Phase II trials of baker's antifol, bleomycin, CCNU, streptozotocin, tilorone, and 5‐fluorodeoxyuridine plus arabinosyl cytosine in metastatic breast cancer

A total of 202 patients with advanced breast cancer were entered into two prospectively randomized Phase II trials conducted by the Eastern Cooperative Oncology Group, in an effort to identify promising agents and combinations for previously treated cases. Patients in Study 1 received bleomycin, CCN...

Full description

Saved in:
Bibliographic Details
Published in:Cancer 1981-08, Vol.48 (3), p.681-685
Main Authors: Cummings, Frank J., Gelman, Rebecca, Skeel, Roland T., Kuperminc, Mario, Israel, Lucien, Colsky, Jacob, Tormey, Douglass
Format: Article
Language:English
Subjects:
Antineoplastic Agents - administration & dosage
Antineoplastic Agents - adverse effects
Bleomycin - administration & dosage
Breast Neoplasms - drug therapy
Breast Neoplasms - mortality
Cytarabine - administration & dosage
Drug Evaluation
Drug Therapy, Combination
Female
Floxuridine - administration & dosage
Humans
Lomustine - administration & dosage
Probability
Streptozocin - administration & dosage
Tilorone - administration & dosage
Triazines - administration & dosage
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A total of 202 patients with advanced breast cancer were entered into two prospectively randomized Phase II trials conducted by the Eastern Cooperative Oncology Group, in an effort to identify promising agents and combinations for previously treated cases. Patients in Study 1 received bleomycin, CCNU, or streptozotocin and those in Study 2 received tilorone, Baker's antifol, or a combination of 5‐fluoro‐deoxyuridine plus arabinosyl cytosine. Partial responses were seen only with bleomycin, Baker's antifol, and 5‐fluorodeoxyuridine plus arabinosyl cytosine. The median times to treatment failure ranged from 3.6 weeks to 5.7 weeks, and the median survival times, from 8 weeks to 25 weeks for tilorone and bleomycin, respectively. Toxic reactions was primarily hematologic and gastrointestinal, but skin, neurologic, respiratory, and renal abnormalities were noted in some treatment arms. The treatment schedules outlined and the toxic effects noted provide background information that might prove useful in designing complex new chemotherapeutic programs, since there is pharmacological rationale for incorporating some of the agents tested into present standard combination chemotherapy regimens.
ISSN:0008-543X
1097-0142
DOI:10.1002/1097-0142(19810801)48:3<681::AID-CNCR2820480304>3.0.CO;2-J